CervoMed Inc. will present the complete Phase 2b RewinD‑LB trial results at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego, Dec 1‑4 2025. The oral presentation on Dec 4, led by Professor John‑Paul Taylor of Newcastle University, will be accompanied by a poster session on Dec 1.
The presentation will showcase 32‑week data from the neflamapimod treatment arm, including clinically meaningful risk reduction and biomarker modulation. Biomarker outcomes such as plasma GFAP, neurofilament light (NfL), and amyloid 42/40 ratios will be discussed, providing a comprehensive view of the drug’s safety and efficacy profile.
The trial’s initial Phase 2b run‑in phase did not meet its primary endpoints, largely because of suboptimal capsule formulation. An extension phase using improved capsules yielded positive results, a development that CervoMed highlighted in its Q3 2025 earnings. The upcoming CTAD presentation will detail these findings and reinforce the scientific rationale for a biomarker‑enriched Phase 3 trial slated for the second half of 2026.
CEO John Alam emphasized that the data “continue to support neflamapimod’s potential as a treatment for DLB” and that the FDA alignment on the Phase 3 design “marks a major milestone for CervoMed.” The presentation is expected to strengthen investor confidence and support the company’s regulatory strategy ahead of the pivotal trial launch.
Analysts have maintained a bullish outlook on CervoMed, with an average recommendation of 1.29 (Strong Buy). The company’s performance has improved, driven in part by the regulatory alignment and the forthcoming presentation of robust clinical data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.